TD SYNNEX (SNX) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $3.06 per share. This compares to earnings of $3.13 per share a year ago. These figures are ...

TD SYNNEX reported upbeat Q4 results, with revenue of $15.85B and EPS of $3.09. Company raised dividend by 10% and expects ...

TD Synnex forecast revenue between $14.4 billion and $15.2 billion for the first quarter, while analysts polled by FactSet expected $14.78 billion. It also guided for adjusted earnings per share in ...

For the current quarter ending in February, TD SYNNEX expects its per-share earnings to range from $2.65 to $3.15. The company said it expects revenue in the range of $14.4 billion to $15.2 billion ...

TD SYNNEX (NYSE: SNX) today announced financial results for the fiscal fourth quarter and fiscal year ended November 30, 2024.

For the quarter ended November 2024, TD SYNNEX (SNX) reported revenue of $15.84 billion, up 10% over the same period last year. EPS came in at $3.09, compared to $3.13 in the year-ago quarter. The ...

Royal Bank of Canada reiterated their outperform rating on shares of TD SYNNEX (NYSE:SNX – Free Report) in a research report released on Tuesday morning,Benzinga reports. Royal Bank of Canada ...

National American University Holdings Inc (NAUH) is expected to report for 2Q. Neogen Corp (NEOG) is expected to report $-0.01 for 2Q. NexImmune Inc (NEXI) is expected to report for 3Q.

US benchmark equity indexes edged down before Friday's opening bell as traders await the national employment situation report for December. Standard & Poor's 500 and the Nasdaq declined 0.1% each in ...

The S&P 500 Index ( $SPX) ( SPY) today are down -1.17%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is down -0.91%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is down -1.49%. March E-mini S&P ...

Paul Aronhime, Senior Vice President of Federal Sector at Keeper Security, the leading provider of zero-trust and zero-knowledge cybersecurity software protecting passwords, passkeys, privileged ...

OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical study, ...